The Mainz-based biotechnology company Biontech delivered 2.6 billion doses of its corona vaccine Comirnaty to 165 countries worldwide last year. Sales in 2021 were almost 19 billion euros. In addition, the company generated a net profit of around 10.3 billion euros. The first approved vaccine based on mRNA technology had a significant impact on health and the global economy, says Biontech CEO Ugur Sahin.
“The financial success enables us to make significant investments in our research and development in the coming years,” said Biontech CFO Jens Holstein.
Up to 1.5 billion euros are to be invested in research and development in 2022, for example in mRNA-based immunotherapies and cell therapies. Vaccines for influenza and shingles are to be promoted.
In addition, it was announced that Biontech plans a share buyback program of up to 1.5 billion US dollars over the next two years and the distribution of a special dividend of two euros per share.
Source: Nachrichten
